|
|
9290 Gaither Road
Gaithersburg, MD 20877 United States
phone:(240) 401-7496
fax:Private
|
|
| Symbol |
|
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.immunomix.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Patented science for application to vaccines and vaccine immunotherapy |
|
| Management |
| Dr. William G. Hearl, Founder & Chief Executive Officer, Board of Directors; Dr. J. Thomas August, Scientific Founder & Chair Scientific Advisory Board; Dr. Bruce F. Mackler, Vice President for Regulatory Affairs; Dr. Teri Jones Heiland, Vice President, Research & Development; Mr. James Wishart, Chief Financial Officer, Board of Directors |
| |
|
|
|
|
|
| Keywords |
| development stage, biotechnology company,vaccines, vaccine immunotherapies |
|
|
|
| Description |
|
Immunomic Therapeutics, Inc. (ITI) is a clinical stage biotechnology company with patented science for application to vaccines and vaccine immunotherapy. |
|
| Products / Services |
LAMP-vax significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP construct(s) have been validated in humans through our license to Geron for LAMP-based telomerase vaccines. GRNVAC1 is currently in the midst of a Phase II and demonstrated both safety and efficacy in AML and prostate cancer patients.
|
|
| Market / Customers |
ITI is focusing its efforts on entering the multi-billion dollar allergy market with a novel immunotherapeutic vaccine. Our innovative clinical trials strategy will enable the company to rapidly progress through the first two phases of clinical study at relatively low expense and position the company for high value exits within three years.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
